Longevity Health Holdings, Inc.
Close on Oct 19, 2026
- Market cap
- $277.24K
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q1 FY2025 Ended Mar 31, 2025 | May 16, 2025 | During market hours | $663.00K | – | – |
Press releases
Announcements Longevity Health filed with the SEC
Longevity Health Holdings Enters into Securities Purchase Agreement for Up to $625,000 in Gross Proceeds
Other events · EX-99.1 to Form 8-K
Longevity Health Holdings Announces Settlement of Litigation with Puritan Partners
Other events · EX-99.1 to Form 8-K
Longevity Health Holdings Closes Strategic Investment and
Material agreement · Unregistered share sale · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
LONGEVITY HEALTH HOLDINGS ANNOUNCES MERGER WITH THPLASMA AND TERMINATION OF 20/20 BIOLABS TRANSACTION
Material agreement · Other events · EX-99.1 to Form 8-K
Longevity Health Holdings, Inc. Announces Successful Fundraising Via ATM Sale
Other events · EX-99.1 to Form 8-K
LONGEVITY HEALTH HOLDINGS ANNOUNCES CONTINUED NASDAQ LISTING TO COMPLETE MERGER WITH 20/20 BIOLABS
Other events · EX-99.1 to Form 8-K
LONGEVITY HEALTH HOLDINGS ANNOUNCES BUSINESS UPDATES
Results of operations · EX-99.1 to Form 8-K
Longevity Health Holdings, Inc. Announces Reverse Stock Split
Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
LONGEVITY HEALTH HOLDINGS ANNOUNCES EXECUTION OF MERGER AGREEMENT WITH 20/20 BIOLABS
Material agreement · Other events · EX-99.1 to Form 8-K
C ARMELL CORP REBRANDS AS LONGEVITY HEALTH HOLDINGS
Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Carmell Announces Closing of Elevai Skincare Acquisition
Acquisition or disposition completed · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Carmell Announces Execution of Definitive Agreement to Acquire Elevai Skincare,
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Carmell Announces PIPE Investment From Existing and New Investors
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
November 2024 A Bio-Aesthetics Revolution
Regulation FD disclosure · EX-99.1 to Form 8-K
CARMELL CORPORATION APPOINTS NEW CEO
Executive or director change · Other events · EX-99.1 to Form 8-K
Carmell Announces $3.0 Million Private Placement
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Carmell Announces Successful Closing of Axolotl Biologix Sale Transaction
Acquisition or disposition completed · Other events · EX-99.1 to Form 8-K
In September 2023, the Company announced the appointment of Mr. Rajiv Shukla as CEO to lead a drive towards near-term profitability and re-positioning as a bio-aesthetics company, that included the following initiatives:
Material agreement · Other events · EX-99.1 to Form 8-K
Carmell Corp Announces Addition of Dr. Bradley Calobrace to Scientific Advisory Board
Other events · EX-99.1 to Form 8-K
Carmell Corp Announces Addition of Dr. Sean Kelishadi to Scientific Advisory Board
Other events · EX-99.1 to Form 8-K
Carmell Corp Announces Addition of Dr. Gregory A. Buford to Scientific Advisory Board
Other events · EX-99.1 to Form 8-K
Carmell Corp Announces Addition of Dr. Adam Rubinstein to Scientific Advisory Board
Other events · EX-99.1 to Form 8-K/A
Carmell Corp Announces Addition of Dr. Jason D. Bloom to Scientific Advisory Board
Other events · EX-99.1 to Form 8-K/A
Carmell Corp Announces Addition of Dr. Adam Rubinstein to Scientific Advisory Board
Other events · EX-99.1 to Form 8-K
Carmell Corp Announces Addition of Dr. Jason D. Bloom to Scientific Advisory Board
Other events · EX-99.1 to Form 8-K
Carmell Corp Announces Addition of Scott Frisch and Gilles Spenlehauer to Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Carmell Announces Successful Closing of Merger with Axolotl Biologix and Launch of a New Brand Identity
Material agreement · Acquisition or disposition completed · Unregistered share sale · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Carmell Therapeutics Announces Merger with Axolotl Biologix, a Profitable Regenerative Medicine Company
Material agreement · Unregistered share sale · Charter or bylaw amendment · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
BACKGROUND/TIMELINE 1. Alpha Healthcare Acquisition Corp. III (Nasdaq: ALPA) announced execution of definitive Merger Agreement with
Material agreement · Unregistered share sale · Charter or bylaw amendment · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION
Material agreement · Acquisition or disposition completed · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Alpha Healthcare Acquisition Corp. III Announces Successful Closing of Business Combination with Carmell Therapeutics Corporation
Material agreement · Acquisition or disposition completed · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.2 to Form 8-K
Carmell Therapeutics Merger With Alpha Healthcare Acquisition Corp III (Nasdaq: ALPA) July 6, 2023
Other events · EX-99.1 to Form 8-K
Alpha Healthcare Acquisition Corp. III Announces Non-Binding Letter of Intent to Acquire a Commercial Stage
Other events · EX-99.1 to Form 8-K
Alpha Healthcare Acquisition Corp. III Announces Merger with Carmell Therapeutics, a Phase 2 Stage Biotechnology Platform Company Developing Allogeneic
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Carmell Therapeutics Merger With Alpha
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.2 to Form 8-K
ALPHA HEALTHCARE ACQUISITION CORP. III
Other events · EX-99.1 to Form 8-K/A